雷诺嗪治疗不稳定型心绞痛患者及对其血清C-反应蛋白水平的影响

摘要

Objective:To study the clinical effect of Ranolazine in treatment of unstable angina pectoris ( UA) ( based on rou-tine therapy) and its influence on serum C-reactive protein level. Methods:100 cases of UA were divided randomly into control group and treatment group. The control group was given routine therapy, besides this, the treatment group was added with Ranolazine by oral-ly taking. The course of treatment was 10 days. Results:The total effective rates in treatment group and control group were 94% and 92%, and there was no significant difference between the two groups (P>0. 05); however, the marked effective rate in treatment group was higher than that in control group (P<0. 05). The serum C-reactive protein concentration in treatment group reduced signifi-cantly compared with that before the treatment (P<0. 05), while it did not change in control group after the treatment (P>0. 05). Conclusions:Based on routine therapy, added Ranolazine can more effectively treat unstable angina, and reduce the level of serum C-reactive protein significantly.%目的：观察常规治疗基础上加用雷诺嗪治疗不稳定型心绞痛患者的临床疗效及对其血清C-反应蛋白水平的影响。方法：将100例不稳定型心绞痛住院患者随机分为对照组和治疗组。对照组患者给予常规治疗，治疗组患者在常规治疗基础上加用雷诺嗪口服治疗，疗程为10 d。结果：治疗组患者总有效率为94%，对照组为92%，两组患者比较差异无显著性(P>0.05)；但治疗组患者的显效率明显高于对照组(P<0.05)，血清C-反应蛋白水平与治疗前比显著下降(P<0.05)，而对照组则无明显变化(P>0.05)。结论：常规治疗基础上加用雷诺嗪治疗不稳定型心绞痛患者疗效优于单纯常规治疗，并能显著降低C-反应蛋白水平。